Pacira BioSciences (PCRX) Superinvestor holders
12 of the superinvestors we track hold Pacira BioSciences (PCRX) in their latest 13F filings, $154M in total.
Summary
The largest holder is David Shaw (D. E. Shaw & Co.), with $49M, 0.0% of the portfolio.
In their latest quarter: 3 opened a new position, 3 added, 4 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| David Shaw D. E. Shaw & Co. |
Trimmed | 1,950,332 | $49M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 1,733,801 | $44M | 0.1% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Added | 1,070,300 | $27M | 0.1% | Q3 2026 |
| Two Sigma Two Sigma Investments |
Added | 724,604 | $18M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 158,511 | $4M | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Held | 132,368 | $3M | 0.2% | Q2 2026 |
| Paul Marshall Marshall Wace |
New position | 129,348 | $3M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
New position | 125,370 | $3M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | 28,243 | $716,525 | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 13,500 | $342,495 | 1.6% | Q2 2026 |
| Acadian Acadian Asset Management |
New position | 12,793 | $319,000 | 0.0% | Q3 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 4,620 | $117,209 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 11 |
| Q4 2025 | 14 |
| Q3 2025 | 13 |
| Q2 2025 | 14 |
| Q1 2025 | 15 |
| Q4 2024 | 16 |
| Q3 2024 | 13 |
Questions about Pacira BioSciences
Which superinvestors own Pacira BioSciences?
12 of the superinvestors we track hold Pacira BioSciences (PCRX) in their latest 13F filings, $154M in total. David Shaw, Jim Simons, Josef Lakonishok, Two Sigma, Cliff Asness, Peter Muller.
Who is the largest superinvestor holder of PCRX?
The largest holder is David Shaw (D. E. Shaw & Co.), with $49M, 0.0% of the portfolio.
From Pacira BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.